Glaukos (GKOS) Stock Price, News & Analysis

Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Key Stats

• Today's Range: $93.20 to $96.71
• 50-Day Range: $81.84 to $161.30
• 52-Week Range: $77.91 to $163.71
• Volume: 545,203 shs
• Average Volume: 646,054 shs
• Market Capitalization: $5.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $156.17
• Consensus Rating: Moderate Buy

Glaukos Stock Analysis - MarketRank™

Glaukos scored higher than 93% of companies evaluated by MarketBeat, and ranked 220th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Glaukos has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Glaukos is -33.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Glaukos is -33.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Glaukos has a P/B Ratio of 10.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.14% of the float of Glaukos has been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Glaukos has recently decreased by 8.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Glaukos does not currently pay a dividend.

Dividend Growth

Glaukos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.90

Percentage of Shares Shorted

6.14% of the float of Glaukos has been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Glaukos has recently decreased by 8.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.84

News Sentiment

Glaukos has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Glaukos this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for GKOS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $665,027.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Glaukos is held by insiders.

Percentage Held by Institutions

99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GKOS Stock Analysis - Frequently Asked Questions

How have GKOS shares performed this year?

Glaukos' stock was trading at $149.94 at the beginning of the year. Since then, GKOS stock has decreased by 35.6% and is now trading at $96.62.
View the best growth stocks for 2025 here.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings results on Thursday, February, 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The medical instruments supplier had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative trailing twelve-month return on equity of 16.53% and a negative net margin of 39.04%.
Read the conference call transcript.

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' top institutional investors include Allspring Global Investments Holdings LLC (0.57%), Riverbridge Partners LLC (0.50%), Rhumbline Advisers (0.25%) and GAMMA Investing LLC (0.24%). Insiders that own company stock include Joseph E Gilliam, Tomas Navratil, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner.
View institutional ownership trends.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 4/27/2025
• Next Earnings (Estimated): 4/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:GKOS
• CIK: 1192448
• Web: www.glaukos.com
• Phone: (949) 367-9600
• Fax: 949-367-9984
• Employees: 780
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $156.17
• High Stock Price Target: $182.00
• Low Stock Price Target: $120.00
• Potential Upside/Downside: +61.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-134,660,000.00
• Net Margins: -39.04%
• Pretax Margin: -41.24%
• Return on Equity: -16.53%
• Return on Assets: -10.61%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 5.54
• Quick Ratio: 4.71

Sales & Book Value

• Annual Sales: $383.48 million
• Price / Sales: 14.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.46 per share
• Price / Book: 10.21

Miscellaneous

• Outstanding Shares: 56,567,000
• Free Float: 51,608,000
• Market Cap: $5.47 billion
• Optionable: Optionable
• Beta: 0.88